Aristides Capital LLC Makes New $205,000 Investment in Immatics (NASDAQ:IMTX)

Aristides Capital LLC purchased a new position in Immatics (NASDAQ:IMTX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 28,900 shares of the company’s stock, valued at approximately $205,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Immatics by 24.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after buying an additional 4,477 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Immatics in the 3rd quarter worth about $298,000. Y Intercept Hong Kong Ltd purchased a new position in Immatics in the 4th quarter worth approximately $211,000. The Manufacturers Life Insurance Company raised its position in shares of Immatics by 9.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock valued at $1,880,000 after buying an additional 13,997 shares in the last quarter. Finally, State Street Corp raised its position in Immatics by 11.2% during the third quarter. State Street Corp now owns 225,202 shares of the company’s stock valued at $2,570,000 after purchasing an additional 22,710 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $16.67.

Immatics Trading Down 8.9 %

IMTX stock opened at $3.50 on Monday. The stock has a market capitalization of $417.75 million, a price-to-earnings ratio of -5.30 and a beta of 0.85. The firm’s 50-day moving average price is $4.81 and its two-hundred day moving average price is $7.13. Immatics has a 12-month low of $3.39 and a 12-month high of $13.77.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million for the quarter, compared to analysts’ expectations of $16.16 million. Equities analysts predict that Immatics will post -0.72 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.